RG 6354

Published

dm+d

Unassigned

New Medicines

Idiopathic pulmonary fibrosis

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

A recombinant form of human pentraxin-2 protein able to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis [1]
IPF affects less than 1.8 in 10,000 people in the EU
Idiopathic pulmonary fibrosis
Intravenous

Myelofibrosis

Information

New molecular entity
Roche
Roche

Development and Regulatory status

None
Phase II Clinical Trials
Phase II Clinical Trials
Yes
Yes

Category

A recombinant form of human pentraxin-2 protein that can regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis [1]
Myelofibrosis may be primary (known as chronic idiopathic myelofibrosis), or secondary to either polycythaemia vera or essential thrombocythaemia. The annual incidence of myelofibrosis is approximately 0.75 per 100,000. The median survival is 5 years from onset, but variation is wide; some patients have a rapidly progressing disorder with short survival. The peak incidence of primary myelofibrosis is between 50 and 70 years of age
Myelofibrosis
Intravenous